Nuvectis Pharma, Inc. financial data

Symbol
NVCT on Nasdaq
Location
1 Bridge Plaza, Suite 275, Fort Lee, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 280 % -7.02%
Debt-to-equity 55.6 % +11.8%
Return On Equity -142 % +8.94%
Return On Assets -91.2 % +12.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.6M shares +32.6%
Common Stock, Shares, Outstanding 25.6M shares +35.1%
Entity Public Float 50M USD -16.7%
Weighted Average Number of Shares Outstanding, Basic 22.7M shares +31.9%
Weighted Average Number of Shares Outstanding, Diluted 22.7M shares +31.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 17.6M USD +38.4%
General and Administrative Expense 8.84M USD +16.7%
Operating Income (Loss) -26.4M USD -30.3%
Net Income (Loss) Attributable to Parent -25.4M USD -31%
Earnings Per Share, Basic -1 USD/shares -18.1%
Earnings Per Share, Diluted -1 USD/shares -18.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.4M USD +106%
Other Assets, Current 145K USD +5.07%
Assets, Current 35.6M USD +106%
Assets 35.6M USD +106%
Accounts Payable, Current 6.44M USD +185%
Employee-related Liabilities, Current 5M USD +32.5%
Accrued Liabilities, Current 65K USD -77%
Liabilities, Current 11.6M USD +83.3%
Liabilities 11.6M USD +83.3%
Retained Earnings (Accumulated Deficit) -92.4M USD -37.9%
Stockholders' Equity Attributable to Parent 24M USD +118%
Liabilities and Equity 35.6M USD +106%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.17M USD +4.22%
Net Cash Provided by (Used in) Financing Activities 15.5M USD +230%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 60M shares 0%
Common Stock, Shares, Issued 25.6M shares +35.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 35.4M USD +106%
Deferred Tax Assets, Valuation Allowance 19.5M USD +34.8%
Deferred Tax Assets, Gross 19.5M USD +34.8%
Deferred Tax Assets, Operating Loss Carryforwards 11.6M USD +20.7%
Additional Paid in Capital 116M USD +49.2%
Deferred Tax Assets, Net of Valuation Allowance 0 USD